Changes in blood concentration and protein binding of the benzodiazepine sedative remimazolam during co-administration with the general anesthetic propofol.

Clarification of changes in plasma concentration and protein binding rate of remimazolam when co-administered with propofol. - Clarification of changes in plasma concentration and protein binding rate of remimazolam when co-administered with propofol.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000060266

Enrollment

Registered

2026-01-06

Start date

2027-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

general anesthesia

Interventions

After the induction of general anesthesia with remimazolam is completed, continuous infusion of propofol is initiated.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing elective surgery under general anesthesia ASA classification 1 to 3 No allergy to remimazolam or propofol Obtain written consent from the person or legally acceptable person

Exclusion criteria

Exclusion criteria: ASA classification 4 or higher Allergic to remimazolam and propofol Written consent cannot be obtained from the person himself/herself or a legal representative

Design outcomes

Primary

Measure	Time frame
Plasma concentration and protein binding rate of remimazolam	—

Countries

Japan

Contacts

Public ContactHiroshi Ueda

Hamamatsu University School of Medicine Department of Medical Education, Faculty of Medicine

hueda-ham@umin.ac.jp0534352738

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026